Bill Text — Aug 2, 2012
This bill’s text is now available.
Aug 2, 2012
112th Congress, 2011–2013
This bill was introduced on August 2, 2012, in a previous session of Congress, but was not enacted.
Senator from Vermont
Read Text »
Last Updated: Aug 2, 2012
Length: 7 pages
A bill to eliminate requirements to undertake duplicative clinical testing of new pharmaceutical drugs, vaccines, biological products, or medical devices, when such duplication is inconsistent with relevant ethical norms.
8/2/2012--Introduced.Ethical Pathway Act of 2012 - Directs the Commissioner of Food and Drugs (FDA) to establish a mechanism by which an applicant to sell any new pharmaceutical drug, vaccine, biologic ... Read more >
The bill’s title was written by its sponsor.
Earlier Version — Introduced
This activity took place on a related bill, S. 3921 (111th).
This is the first step in the legislative process.
This is a Senate bill in the United States Congress (indicated by the “S.” in “S. 3506”). A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The committee chair determines whether a bill will move past the committee stage.
There have been no roll call votes related to this bill.
Click a format for a citation suggestion:
Civic Impulse. (2015). S. 3506 — 112th Congress: Ethical Pathway Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/s3506
“S. 3506 — 112th Congress: Ethical Pathway Act of 2012.” www.GovTrack.us. 2012. November 24, 2015 <https://www.govtrack.us/congress/bills/112/s3506>
|title=S. 3506 (112th)
|accessdate=November 24, 2015
|author=112th Congress (2012)
|date=August 2, 2012
|quote=Ethical Pathway Act of 2012